Cervical cancer prevention by vaccination: review
AbstractRoutine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an uncertain future.ObjectiveTo review th...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-04-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1386167/full |
| _version_ | 1797193848889278464 |
|---|---|
| author | Julio Cesar González-Rodríguez Aurelio Cruz-Valdez Vicente Madrid-Marina |
| author_facet | Julio Cesar González-Rodríguez Aurelio Cruz-Valdez Vicente Madrid-Marina |
| author_sort | Julio Cesar González-Rodríguez |
| collection | DOAJ |
| description | AbstractRoutine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an uncertain future.ObjectiveTo review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination as adjuvant management. This review aims to describe the current state of vaccination programs and demonstrate the long-term protection and safety of vaccines implemented worldwide targeting adolescent girls, with the most recent published evidence of the three prophylactic HPV vaccines – bivalent (bHPV), quadrivalent (qHPV), and nonavalent (nHPV)-. We mainly focus on publications evaluating efficacy, dosing schemes, and HPV vaccination, as well as studies contributing to the mounting evidence for the real-life effectiveness of prophylactic HPV vaccines from several countries.FindingsHuman Papillomavirus vaccination programs have made remarkable strides in preventing HPV-related diseases; countries with robust vaccination efforts have witnessed substantial reductions in HPV-related diseases with a decline in high-grade cervical abnormalities and genital warts (54%-83%). However, global coverage remains uneven, with disparities between high-income (HICs) and low-income countries (LMICs). The long-term efficacy of the available human papillomavirus (HPV) goes up to 9.4 years and continues to be immunogenic and well tolerated with an excellent safety profile.Conclusions and relevanceAs these are crucial topics in HPV vaccination, it is essential to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time. |
| first_indexed | 2024-04-24T05:46:55Z |
| format | Article |
| id | doaj.art-61435089409643288f6e4afbcfe0e310 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-24T05:46:55Z |
| publishDate | 2024-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-61435089409643288f6e4afbcfe0e3102024-04-23T13:46:13ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-04-011410.3389/fonc.2024.13861671386167Cervical cancer prevention by vaccination: reviewJulio Cesar González-Rodríguez0Aurelio Cruz-Valdez1Vicente Madrid-Marina2Department of Oncology Gynecology, Instituto Nacional de Cancerología (INCAN), México City, MexicoCenter for Population Health Research, Instituto Nacional de Salud Pública (INSP), Cuernavaca, MexicoChronic Infections and Cancer Division, Center for Research on Infectious Diseases, Instituto Nacional de Salud Pública (INSP), Cuernavaca, MexicoAbstractRoutine use of human papillomavirus (HPV) vaccines is recommended in adolescents under 15 years of age worldwide. Still, effective programs remain suboptimal for several factors, making the WHO strategy to eradicate cervical cancer public health with an uncertain future.ObjectiveTo review the literature on the effectiveness, long-term protection, and safety of HPV vaccination programs and vaccination as adjuvant management. This review aims to describe the current state of vaccination programs and demonstrate the long-term protection and safety of vaccines implemented worldwide targeting adolescent girls, with the most recent published evidence of the three prophylactic HPV vaccines – bivalent (bHPV), quadrivalent (qHPV), and nonavalent (nHPV)-. We mainly focus on publications evaluating efficacy, dosing schemes, and HPV vaccination, as well as studies contributing to the mounting evidence for the real-life effectiveness of prophylactic HPV vaccines from several countries.FindingsHuman Papillomavirus vaccination programs have made remarkable strides in preventing HPV-related diseases; countries with robust vaccination efforts have witnessed substantial reductions in HPV-related diseases with a decline in high-grade cervical abnormalities and genital warts (54%-83%). However, global coverage remains uneven, with disparities between high-income (HICs) and low-income countries (LMICs). The long-term efficacy of the available human papillomavirus (HPV) goes up to 9.4 years and continues to be immunogenic and well tolerated with an excellent safety profile.Conclusions and relevanceAs these are crucial topics in HPV vaccination, it is essential to establish systems for continued monitoring of vaccine immunogenicity, efficacy, and safety over time.https://www.frontiersin.org/articles/10.3389/fonc.2024.1386167/fullhuman papillomavirusesHPVProphylactic HPV vaccineseffectivenessHPV Vaccines |
| spellingShingle | Julio Cesar González-Rodríguez Aurelio Cruz-Valdez Vicente Madrid-Marina Cervical cancer prevention by vaccination: review Frontiers in Oncology human papillomaviruses HPV Prophylactic HPV vaccines effectiveness HPV Vaccines |
| title | Cervical cancer prevention by vaccination: review |
| title_full | Cervical cancer prevention by vaccination: review |
| title_fullStr | Cervical cancer prevention by vaccination: review |
| title_full_unstemmed | Cervical cancer prevention by vaccination: review |
| title_short | Cervical cancer prevention by vaccination: review |
| title_sort | cervical cancer prevention by vaccination review |
| topic | human papillomaviruses HPV Prophylactic HPV vaccines effectiveness HPV Vaccines |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1386167/full |
| work_keys_str_mv | AT juliocesargonzalezrodriguez cervicalcancerpreventionbyvaccinationreview AT aureliocruzvaldez cervicalcancerpreventionbyvaccinationreview AT vicentemadridmarina cervicalcancerpreventionbyvaccinationreview |